Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
20.54
+0.13 (0.64%)
Apr 6, 2026, 10:13 AM EDT - Market open
Zai Lab Revenue
In the year 2025, Zai Lab had annual revenue of $460.16M with 15.33% growth. Zai Lab had revenue of $127.60M in the quarter ending December 31, 2025, with 16.99% growth.
Revenue (ttm)
$460.16M
Revenue Growth
+15.33%
P/S Ratio
5.00
Revenue / Employee
$257,935
Employees
1,784
Market Cap
2.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 460.16M | 61.17M | 15.33% |
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 673.00M |
| ADMA Biologics | 510.17M |
| Adaptive Biotechnologies | 276.98M |
| Syndax Pharmaceuticals | 172.35M |
| Day One Biopharmaceuticals | 158.18M |
| Nektar Therapeutics | 55.23M |
| Relay Therapeutics | 15.36M |
| Celldex Therapeutics | 1.55M |
ZLAB News
- 5 days ago - Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy - Business Wire
- 17 days ago - Insider Buying: Richard Gaynor Acquires Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 18 days ago - JP Morgan Lowers Price Target for Zai Lab (ZLAB) to $32 | ZLAB Stock News - GuruFocus
- 19 days ago - Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) - Business Wire
- 4 weeks ago - Insider Sell: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 4 weeks ago - Insider Sell Alert: Rafael Amado Sells 10,000 Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 5 weeks ago - Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight - GuruFocus
- 5 weeks ago - Zai Lab Ltd (ZLAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus